Cihlar T - Search Results

1

Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys.

Mackman RL, Kalla RV, Babusis D, Pitts J, Barrett KT, Chun K, Du Pont V, Rodriguez L, Moshiri J, Xu Y, Lee M, Lee G, Bleier B, Nguyen AQ, O'Keefe BM, Ambrosi A, Cook M, Yu J, Dempah KE, Bunyan E, Riola NC, Lu X, Liu R, Davie A, Hsiang TY, Dearing J, Vermillion M, Gale M Jr, Niedziela-Majka A, Feng JY, Hedskog C, Bilello JP, Subramanian R, Cihlar T. Mackman RL, et al. Among authors: cihlar t. J Med Chem. 2023 Sep 14;66(17):11701-11717. doi: 10.1021/acs.jmedchem.3c00750. Epub 2023 Aug 19. J Med Chem. 2023. PMID: 37596939 Free PMC article.

2

Novel targets for HIV therapy.

Greene WC, Debyser Z, Ikeda Y, Freed EO, Stephens E, Yonemoto W, Buckheit RW, Esté JA, Cihlar T. Greene WC, et al. Among authors: cihlar t. Antiviral Res. 2008 Dec;80(3):251-65. doi: 10.1016/j.antiviral.2008.08.003. Epub 2008 Sep 30. Antiviral Res. 2008. PMID: 18789977

3

Unlikely association of multidrug-resistance protein 2 single-nucleotide polymorphisms with tenofovir-induced renal adverse events.

Ray AS, Cihlar T. Ray AS, et al. Among authors: cihlar t. J Infect Dis. 2007 May 1;195(9):1389-90; author reply 1390-1. doi: 10.1086/513282. J Infect Dis. 2007. PMID: 17397012 No abstract available.

4

In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.

Vidal F, Domingo JC, Guallar J, Saumoy M, Cordobilla B, Sánchez de la Rosa R, Giralt M, Alvarez ML, López-Dupla M, Torres F, Villarroya F, Cihlar T, Domingo P. Vidal F, et al. Among authors: cihlar t. Antimicrob Agents Chemother. 2006 Nov;50(11):3824-32. doi: 10.1128/AAC.00437-06. Epub 2006 Aug 28. Antimicrob Agents Chemother. 2006. PMID: 16940060 Free PMC article.

5

Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.

Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, Spinner A, Jerome C, Moore J, Kearney BP, Marthas ML, Reiser H, Bischofberger N. Van Rompay KK, et al. Among authors: cihlar t. Antimicrob Agents Chemother. 2008 Sep;52(9):3144-60. doi: 10.1128/AAC.00350-08. Epub 2008 Jun 23. Antimicrob Agents Chemother. 2008. PMID: 18573931 Free PMC article.

6

Phosphorylation of 9-(2-phosphonomethoxyethyl)adenine and 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine by AMP(dAMP) kinase from L1210 cells.

Merta A, Votruba I, Jindrich J, Holý A, Cihlár T, Rosenberg I, Otmar M, Herve TY. Merta A, et al. Among authors: cihlar t. Biochem Pharmacol. 1992 Nov 17;44(10):2067-77. doi: 10.1016/0006-2952(92)90110-5. Biochem Pharmacol. 1992. PMID: 1449524

7

GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system.

Hruz PW, Yan Q, Tsai L, Koster J, Xu L, Cihlar T, Callebaut C. Hruz PW, et al. Among authors: cihlar t. Antimicrob Agents Chemother. 2011 Apr;55(4):1377-82. doi: 10.1128/AAC.01184-10. Epub 2011 Jan 18. Antimicrob Agents Chemother. 2011. PMID: 21245443 Free PMC article.

8

Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance.

Seo SK, Regan A, Cihlar T, Lin DC, Boulad F, George D, Prasad VK, Kiehn TE, Polsky B. Seo SK, et al. Among authors: cihlar t. Clin Infect Dis. 2001 Nov 1;33(9):e105-8. doi: 10.1086/323022. Epub 2001 Sep 26. Clin Infect Dis. 2001. PMID: 11577375

9

Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication.

Andrei G, Lisco A, Vanpouille C, Introini A, Balestra E, van den Oord J, Cihlar T, Perno CF, Snoeck R, Margolis L, Balzarini J. Andrei G, et al. Among authors: cihlar t. Cell Host Microbe. 2011 Oct 20;10(4):379-89. doi: 10.1016/j.chom.2011.08.015. Cell Host Microbe. 2011. PMID: 22018238 Free PMC article.

10

The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.

Hill G, Cihlar T, Oo C, Ho ES, Prior K, Wiltshire H, Barrett J, Liu B, Ward P. Hill G, et al. Among authors: cihlar t. Drug Metab Dispos. 2002 Jan;30(1):13-9. doi: 10.1124/dmd.30.1.13. Drug Metab Dispos. 2002. PMID: 11744606 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

154 results

Search Page

Filters